perfusion bioreactor platform Search Results


90
BioMimetic Therapeutics perfusion bioreactor platform
Perfusion Bioreactor Platform, supplied by BioMimetic Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/perfusion+bioreactor+platform/biomimetic+perfusion+system/pm38969078-3-11-4
Average 90 stars, based on 1 article reviews
perfusion bioreactor platform - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Getinge AB mini-bioreactor system
High‐density culture of S6 derived erythroid cells in perfusion <t>bioreactor.</t> (A) Mesoderm/primitive‐streak (T‐bra) and haematopoietic fated mesoderm markers (KDR+) examined at differentiation D3 by flow cytometry. (B) haematopoietic progenitor markers (CD34+CD43+, CD34+CD45+) and committed haematopoietic cells (CD34‐CD43+, CD34‐CD45+) at day 11 examined by flow cytometry. (C) Erythroblasts markers CD235a and CD71 evaluated for day 16 erythroblasts by flow cytometry prior to bioreactor culture. (D) Representative Giemsa staining of S6 derived day 16 erythroblasts. (E) S6‐derived erythroblast expansion and cell viability in perfusion bioreactor and control spinner flask with same culture volume (P1 – perfusion start point; P2/3 – first/second increase in perfusion flow rate; D1/2/3 – first/second/third DO change). * p < 0.05 comparing bioreactor versus spinner growth. (F) Comparison of erythroblast markers CD235a and CD71 for day 20 and day 24 erythroblasts cultured in spinner flasks and bioreactor. Data shown from a highly successful individual bioreactor run & two parallel spinner flasks
Mini Bioreactor System, supplied by Getinge AB, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/perfusion+bioreactor+platform/minibio+bioreactor/pmc09357363-35-8-7
Average 90 stars, based on 1 article reviews
mini-bioreactor system - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

hep g2  (ATCC)
99
ATCC hep g2
High‐density culture of S6 derived erythroid cells in perfusion <t>bioreactor.</t> (A) Mesoderm/primitive‐streak (T‐bra) and haematopoietic fated mesoderm markers (KDR+) examined at differentiation D3 by flow cytometry. (B) haematopoietic progenitor markers (CD34+CD43+, CD34+CD45+) and committed haematopoietic cells (CD34‐CD43+, CD34‐CD45+) at day 11 examined by flow cytometry. (C) Erythroblasts markers CD235a and CD71 evaluated for day 16 erythroblasts by flow cytometry prior to bioreactor culture. (D) Representative Giemsa staining of S6 derived day 16 erythroblasts. (E) S6‐derived erythroblast expansion and cell viability in perfusion bioreactor and control spinner flask with same culture volume (P1 – perfusion start point; P2/3 – first/second increase in perfusion flow rate; D1/2/3 – first/second/third DO change). * p < 0.05 comparing bioreactor versus spinner growth. (F) Comparison of erythroblast markers CD235a and CD71 for day 20 and day 24 erythroblasts cultured in spinner flasks and bioreactor. Data shown from a highly successful individual bioreactor run & two parallel spinner flasks
Hep G2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/perfusion+bioreactor+platform/Hep+G2/custom%40hb-8065%4023410914
Average 99 stars, based on 1 article reviews
hep g2 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

Image Search Results


High‐density culture of S6 derived erythroid cells in perfusion bioreactor. (A) Mesoderm/primitive‐streak (T‐bra) and haematopoietic fated mesoderm markers (KDR+) examined at differentiation D3 by flow cytometry. (B) haematopoietic progenitor markers (CD34+CD43+, CD34+CD45+) and committed haematopoietic cells (CD34‐CD43+, CD34‐CD45+) at day 11 examined by flow cytometry. (C) Erythroblasts markers CD235a and CD71 evaluated for day 16 erythroblasts by flow cytometry prior to bioreactor culture. (D) Representative Giemsa staining of S6 derived day 16 erythroblasts. (E) S6‐derived erythroblast expansion and cell viability in perfusion bioreactor and control spinner flask with same culture volume (P1 – perfusion start point; P2/3 – first/second increase in perfusion flow rate; D1/2/3 – first/second/third DO change). * p < 0.05 comparing bioreactor versus spinner growth. (F) Comparison of erythroblast markers CD235a and CD71 for day 20 and day 24 erythroblasts cultured in spinner flasks and bioreactor. Data shown from a highly successful individual bioreactor run & two parallel spinner flasks

Journal: Cell Proliferation

Article Title: Selection of O‐negative induced pluripotent stem cell clones for high‐density red blood cell production in a scalable perfusion bioreactor system

doi: 10.1111/cpr.13218

Figure Lengend Snippet: High‐density culture of S6 derived erythroid cells in perfusion bioreactor. (A) Mesoderm/primitive‐streak (T‐bra) and haematopoietic fated mesoderm markers (KDR+) examined at differentiation D3 by flow cytometry. (B) haematopoietic progenitor markers (CD34+CD43+, CD34+CD45+) and committed haematopoietic cells (CD34‐CD43+, CD34‐CD45+) at day 11 examined by flow cytometry. (C) Erythroblasts markers CD235a and CD71 evaluated for day 16 erythroblasts by flow cytometry prior to bioreactor culture. (D) Representative Giemsa staining of S6 derived day 16 erythroblasts. (E) S6‐derived erythroblast expansion and cell viability in perfusion bioreactor and control spinner flask with same culture volume (P1 – perfusion start point; P2/3 – first/second increase in perfusion flow rate; D1/2/3 – first/second/third DO change). * p < 0.05 comparing bioreactor versus spinner growth. (F) Comparison of erythroblast markers CD235a and CD71 for day 20 and day 24 erythroblasts cultured in spinner flasks and bioreactor. Data shown from a highly successful individual bioreactor run & two parallel spinner flasks

Article Snippet: A successful perfusion culture platform in the Applikon mini‐bioreactor system can potentially be scaled up to larger controlled bioreactors, thus paving the way for large‐scale manufacturing of high cell density erythroblasts and RBCs.

Techniques: Derivative Assay, Flow Cytometry, Staining, Cell Culture